The Blog

CAR-T Cell Therapy vs. Bispecific Antibody Therapies in Relapsed Lymphoma

The prognosis for relapsed/refractory large B cell lymphoma has historically been poor. But response to novel CAR-T cell and bispecific T cell engagers show curative potential.

Read the post